These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24429195)

  • 1. American Society of Clinical Oncology Annual Meeting 2013.
    Yaqub F
    Lancet Respir Med; 2013 Jul; 1(5):360-1. PubMed ID: 24429195
    [No Abstract]   [Full Text] [Related]  

  • 2. 2015 American Society of Clinical Oncology annual meeting.
    Cleghorn S
    Lancet Respir Med; 2015 Jul; 3(7):516-7. PubMed ID: 26078097
    [No Abstract]   [Full Text] [Related]  

  • 3. Ceritinib versus chemotherapy in ALK-positive lung cancer.
    Marshall H
    Lancet Respir Med; 2016 Dec; 4(12):952-953. PubMed ID: 27838332
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies].
    Thonnard AS; Bosquée L; Corhay JL
    Rev Med Liege; 2011 Mar; 66(3):121-5. PubMed ID: 21560426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [TRUST study: general practice relevant data on erlotinib in NSCLC].
    Knabl A
    Wien Med Wochenschr; 2007; 157(21-22):579-80. PubMed ID: 18157598
    [No Abstract]   [Full Text] [Related]  

  • 6. [Non-small cell lung cancer: Remarkable developments].
    Vignot S; Wislez M
    Bull Cancer; 2015 Dec; 102(12):962-3. PubMed ID: 26597477
    [No Abstract]   [Full Text] [Related]  

  • 7. Network meta-analysis: importance of appropriate trial selection.
    Edwards SJ; Borrill J
    Value Health; 2010 Aug; 13(5):681-2; author reply 683. PubMed ID: 20345543
    [No Abstract]   [Full Text] [Related]  

  • 8. 2004 highlights from: 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 2004.
    Price N; Reddy GK
    Clin Lung Cancer; 2004 Jul; 6(1):11-6. PubMed ID: 15310411
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of non-small cell lung cancer: focus on erlotinib. Foreword.
    Cappuzzo F
    Drugs; 2012 Jun; 72 Suppl 1():1-2. PubMed ID: 22712791
    [No Abstract]   [Full Text] [Related]  

  • 10. Medical treatment of non-small-cell lung cancer.
    Buter J; Giaccone G
    Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
    [No Abstract]   [Full Text] [Related]  

  • 11. Gefitinib or docetaxel in advanced non-small-cell lung cancer.
    Cullen M; Thatcher N
    Lancet; 2008 Nov; 372(9652):1785-6. PubMed ID: 19027472
    [No Abstract]   [Full Text] [Related]  

  • 12. Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
    Liu D; Yang Y; Zhao S
    J Formos Med Assoc; 2014 Mar; 113(3):141-2. PubMed ID: 24630031
    [No Abstract]   [Full Text] [Related]  

  • 13. Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv158-iv161. PubMed ID: 28881928
    [No Abstract]   [Full Text] [Related]  

  • 14. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
    Garassino MC; Martelli O; Broggini M; Farina G; Veronese S; Rulli E; Bianchi F; Bettini A; Longo F; Moscetti L; Tomirotti M; Marabese M; Ganzinelli M; Lauricella C; Labianca R; Floriani I; Giaccone G; Torri V; Scanni A; Marsoni S;
    Lancet Oncol; 2013 Sep; 14(10):981-8. PubMed ID: 23883922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
    Tsujino K; Kawaguchi T; Kubo A; Aono N; Nakao K; Koh Y; Tachibana K; Isa S; Takada M; Kurata T
    J Thorac Oncol; 2009 Aug; 4(8):994-1001. PubMed ID: 19633474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Is it possible to treat bronchial carcinoma without chemotherapy?].
    Pujol JL
    Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S23-10S26. PubMed ID: 17127957
    [No Abstract]   [Full Text] [Related]  

  • 17. Three new drugs available to fight kidney cancer.
    Bankhead C
    J Natl Cancer Inst; 2006 Sep; 98(17):1181-2. PubMed ID: 16954469
    [No Abstract]   [Full Text] [Related]  

  • 18. Gefitinib in the treatment of advanced non-small-cell lung cancer.
    Reck M
    Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.
    Cromwell I; van der Hoek K; Melosky B; Peacock S
    J Thorac Oncol; 2011 Dec; 6(12):2097-103. PubMed ID: 22052223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
    Wong AS; Seto KY; Chin TM; Soo RA
    J Thorac Oncol; 2008 Sep; 3(9):1077-8. PubMed ID: 18758318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.